Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 10, 2013, Pages 2165-2177

  Tamminga, Cindy ^a   Sedegah, Martha ^a   Maiolatesi, Santina ^a   Fedders, Charlotte ^a   Reyes, Sharina ^a   Reyes, Anatalio ^a   Vasquez, Carlos ^a   Alcorta, Yolanda ^a   Chuang, Ilin ^a   Spring, Michele ^f   Kavanaugh, Michael ^c   Ganeshan, Harini ^a   Huang, Jun ^a   Belmonte, Maria ^a   Abot, Esteban ^a   Belmonte, Arnel ^a   Banania, Joglenna ^a   Farooq, Fouzia ^a   Murphy, Jittawadee ^b   Komisar, Jack ^b   Richie, Nancy O ^b   Bennett, Jason ^b   Limbach, Keith ^a   Bpatterson, Noelle ^a   Bruder, Joseph T ^e   Shi, Meng ^b   Miller, Edward ^c   Dutta, Sheetij ^b   Diggs, Carter ^d   Soisson, Lorraine A ^d   Hollingdale, Michael R ^a   Epstein, Judith E ^a   Richie, Thomas L ^a   more..

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^e GENVEC INC   (United States)

^f ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

Author keywords

Adenovirus; Antibody; Efficacy; Malaria; T cells; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; APICAL MEMBRANE ANTIGEN 1; CIRCUMSPOROZOITE PROTEIN; GAMMA INTERFERON; MALARIA VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; AXILLA LYMPHADENOPATHY; AXILLARY LYMPHADENOPATHY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYTOKINE PRODUCTION; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPRESSION VECTOR; EYE IRRITATION; EYE PAIN; FATIGUE; FEMALE; FEVER; FLOW CYTOMETRY; HEADACHE; HEMATURIA; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; MYALGIA; NAUSEA; NEUTROPENIA; NOSE OBSTRUCTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PROTEIN DETERMINATION; PROTEINURIA; RASH; SIDE EFFECT; SWEATING; URINARY FREQUENCY; URTICARIA; VIRAL GENE DELIVERY SYSTEM; VOMITING;

ADENOVIRUS; ANTIBODY; EFFICACY; MALARIA; T CELLS; VACCINE;

ADENOVIRUSES, HUMAN; ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84879105006     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24941     Document Type: Article

References (32)

1. Overstreet MG, Cockburn IA, Chen YC, Zavala F. Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. Immunol Rev 2008;225:272-83; PMID: 18837788; http://dx.doi. Org/10.1111/j.1600-065X.2008.00671.x
2. Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, Harty JT. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 2011;9:451-62; PMID:21669394; http://dx.doi. Org/10.1016/j. chom.2011.05.008
3. Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS, S: a review of the available data. Malar J 2009;8:312; PMID:20042088; http://dx.doi.org/l 0.1186/1475-2875-8-312
4. Halstead SB, Thomas SJ. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines 2011;10:355-64; PMID:21434803; http://dx.doi.org/10.1586/erv.1L7
5. Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, Lejano J, et al. Adenovirus 5-vectored P falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One 2011;6:e24586; PMID:22003383; http://dx.doi.org/10.1371/journal, pone. 00245 86
6. Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, Collins KA, Edwards NJ, Douglas AD, Anagnostou NA, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 2012;20:2355-68; PMID =23089736; http://dx.doi.org/10.1038/mt.2012.223
7. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 2005;102:4836-41; PMID: 15781866; http://dx.doi.org/10.1073/ pnas.0406381102
8. Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, Carucci DJ, et al. Induction of CD4 (+) T cell-dependent CD8 (+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 2001;98:10817-22; PMID: 11526203; http://dx.doi.org/10.1073/pnas. 181123498
9. Wang R, Doolan DL, Charoenvit Y, Hedstrom RC, Gardner MJ, Hobart P, et al. Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids. Infect Immun 1998;66:4193-202; PMID:9712767
10. + T-cell responses. Infect Immun 2010;78:145-53; PMID: 19858306; http://dx.doi.org/10.1128/IAI. 00740-09
11. Jiang G, Shi M, Conteh S, Richie N, Banania G, Geneshan H, et al. Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies. PLoS One 2009;4:e6559; PMID: 19668343; http://dx.doi.org/10.1371/jo urnal. pone.0006559
12. Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A 1994;91:9866-70; PMID:7937907; http://dx.doi.org/10.1073/pnas. 91.21.9866
13. Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000;18:1893-901; PMID: 10699338; http://dx.doi.org/10.1016/S0264-410X (99) 00407-7
14. Epstein JE, Gorak EJ, Charoenvit Y, Wang R, Freydberg N, Osinowo O, et al. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needlefree jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther 2002;13:1551-60; PMID:12228010; http://dx.doi.org/10.1089/ 10430340260201644
15. Richie TL, Charoenvit Y, Wang R, Epstein JE, Hedstrom RC, Kumar S, et al. Clinical trial in healthy malaria-naive adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStD05, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccin Immunother 2012;8:1564-84; PMID:23151451; http://dx.doi.org/10.4161/hv. 22129
16. Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, et al. DNA prime/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cellmediated immunity. PLoS ONE 2013;8:e55571; PMID:23457473
17. Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, Spring M, et al. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 2011;6:e25868; PMID:22003411; http://dx.doi.org/l 0.1371/journal, pone. 0025 868
18. Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, et al. Quantifying adenovirusneutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 2003;41:5046-52; PMID: 14605137; http://dx.doi.org/10.1128/JCM. 41.11.5046-5052.2003
19. Chulay JD, Schneider I, Cosgriff TM, Hoffman SL, Ballou WR, Quakyi I A, et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 1986;35:66-8; PMID:3511753
20. Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, et al. Phase la clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 2012;7:e31208; PMID:22363582; http://dx.doi.org/10.1371/journal. pone.0031208
21. Good MF, Quakyi IA, Saul A, Berzofsky JA, Carter R, Miller LH. Human T clones reactive to the sexual stages of Plasmodium falciparum malaria. High frequency of gamete-reactive T cells in peripheral blood from nonexposed donors. J Immunol 1987;138:306-11; PMID:2431058
22. Fell AH, Silins SL, Baumgarth N, Good MF. Plasmodium falciparum-specific T cell clones from non-exposed and exposed donors are highly diverse in TCR beta chain V segment usage. Int Immunol 1996;8:1877-87; PMID:8982772; http://dx.doi.org/10.1093/intimm/8.12.1877
23. Holst PJ, Orskov C, Thomsen AR, Christensen JR Quality of the transgene-specific CD 8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination. J Immunol 2010;184:4431-9; PMID:20212099; http://dx.doi.org/10.4049/j immunol. 09 005 37
24. De Rosa SC, Thomas EP, Bui J, Huang Y, De Camp A, Morgan C, et al.; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol 2011;187:3391-401; PMID:21844392; http://dx.doi.org/10.4049/jimmunol.1101421
25. + T cells. J Immunother 2010;33:510-22; PMID:2 04635 96; http://dx.doi.org/10.1097/CJI.0b013e3181d75cef
26. + T effector memory cells protect against liver-stage malaria. J Immunol 2011;187:1347-57; PMID:21715686; http://dx.doi.org/10.4049/j immunol. 1100302
27. +T cells against liver-stage malaria. PLoS One 2009;4:e5075; PMID:19347042; http: 11 dx. do i.org/10.13 71/j o u rnal. pone. 000 5 075
28. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008;8:247-58; PMID: 18323851; http://dx.doi.org/10.1038/nri2274
29. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Lab oratory-based versus non-laboratorybased method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 2008;371:923-31; PMID: 18342687; http://dx.doi.org/10.1016/S0l40-6736 (08) 604l8-3
30. Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, et al.; Merck V520-007/012 Study Teams. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses 2009;25:103-14; PMID: 19108693; http://dx.doi.org/10.1089/aid.2008.0212
31. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS, S Malaria Vaccine Evaluation Group. N Engl J Med 1997;336:86-91; PMID:8988885; http://dx.doi.org/10.105 6/NEJM199701093360202
32. McGill R. Variations of Box Plots. Am Stat 1978;32:12-6